Selected research
Industry Research
Antiviral Drugs for Influenza Industry Research Report 2026
Market perspective
The global Antiviral Drugs for Influenza market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Antiviral Drugs for Influenza is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Antiviral Drugs for Influenza is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Antiviral Drugs for Influenza is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Antiviral Drugs for Influenza include AdvaCare Pharma, Avexima, BioCryst Pharmaceuticals, Daiichi Sankyo, Morningside Pharmaceuticals, Shionogi, Wockhardt, GlaxoSmithKline and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Antiviral Drugs for Influenza market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Antiviral Drugs for Influenza Market by Company
AdvaCare Pharma
Avexima
BioCryst Pharmaceuticals
Daiichi Sankyo
Morningside Pharmaceuticals
Shionogi
Wockhardt
GlaxoSmithKline
Roche
Teva Pharmaceuticals
Antiviral Drugs for Influenza Segment by Type
Neuraminidase Inhibitors
Polymerase Inhibitors
Antiviral Drugs for Influenza Segment by Application
Over-the-counter (OTC)
Prescription (Rx)
Antiviral Drugs for Influenza Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antiviral Drugs for Influenza market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antiviral Drugs for Influenza and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antiviral Drugs for Influenza.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Antiviral Drugs for Influenza manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Antiviral Drugs for Influenza by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Antiviral Drugs for Influenza in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Neuraminidase Inhibitors
- Polymerase Inhibitors
Applications
- Over-the-counter (OTC)
- Prescription (Rx)
Companies covered
- AdvaCare Pharma
- Avexima
- BioCryst Pharmaceuticals
- Daiichi Sankyo
- Morningside Pharmaceuticals
- Shionogi
- Wockhardt
- GlaxoSmithKline
- Roche
- Teva Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Antiviral Drugs for Influenza Market Size (2021-2032)
- 2.2.2 Global Antiviral Drugs for Influenza Sales (2021-2032)
- 2.2.3 Global Antiviral Drugs for Influenza Market Average Price (2021-2032)
- 2.3 Antiviral Drugs for Influenza by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Neuraminidase Inhibitors
- 2.3.3 Polymerase Inhibitors
- 2.4 Antiviral Drugs for Influenza by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Over-the-counter (OTC)
- 2.4.3 Prescription (Rx)
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Antiviral Drugs for Influenza Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Antiviral Drugs for Influenza Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Antiviral Drugs for Influenza Revenue of Manufacturers (2021-2026)
- 3.4 Global Antiviral Drugs for Influenza Average Price by Manufacturers (2021-2026)
- 3.5 Global Antiviral Drugs for Influenza Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Antiviral Drugs for Influenza, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Antiviral Drugs for Influenza, Product Type & Application
- 3.8 Global Manufacturers of Antiviral Drugs for Influenza, Established Date
- 3.9 Global Antiviral Drugs for Influenza Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 AdvaCare Pharma
- 4.1.1 AdvaCare Pharma Company Information
- 4.1.2 AdvaCare Pharma Business Overview
- 4.1.3 AdvaCare Pharma Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 AdvaCare Pharma Antiviral Drugs for Influenza Product Portfolio
- 4.1.5 AdvaCare Pharma Recent Developments
- 4.2 Avexima
- 4.2.1 Avexima Company Information
- 4.2.2 Avexima Business Overview
- 4.2.3 Avexima Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Avexima Antiviral Drugs for Influenza Product Portfolio
- 4.2.5 Avexima Recent Developments
- 4.3 BioCryst Pharmaceuticals
- 4.3.1 BioCryst Pharmaceuticals Company Information
- 4.3.2 BioCryst Pharmaceuticals Business Overview
- 4.3.3 BioCryst Pharmaceuticals Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 BioCryst Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio
- 4.3.5 BioCryst Pharmaceuticals Recent Developments
- 4.4 Daiichi Sankyo
- 4.4.1 Daiichi Sankyo Company Information
- 4.4.2 Daiichi Sankyo Business Overview
- 4.4.3 Daiichi Sankyo Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Daiichi Sankyo Antiviral Drugs for Influenza Product Portfolio
- 4.4.5 Daiichi Sankyo Recent Developments
- 4.5 Morningside Pharmaceuticals
- 4.5.1 Morningside Pharmaceuticals Company Information
- 4.5.2 Morningside Pharmaceuticals Business Overview
- 4.5.3 Morningside Pharmaceuticals Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Morningside Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio
- 4.5.5 Morningside Pharmaceuticals Recent Developments
- 4.6 Shionogi
- 4.6.1 Shionogi Company Information
- 4.6.2 Shionogi Business Overview
- 4.6.3 Shionogi Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Shionogi Antiviral Drugs for Influenza Product Portfolio
- 4.6.5 Shionogi Recent Developments
- 4.7 Wockhardt
- 4.7.1 Wockhardt Company Information
- 4.7.2 Wockhardt Business Overview
- 4.7.3 Wockhardt Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Wockhardt Antiviral Drugs for Influenza Product Portfolio
- 4.7.5 Wockhardt Recent Developments
- 4.8 GlaxoSmithKline
- 4.8.1 GlaxoSmithKline Company Information
- 4.8.2 GlaxoSmithKline Business Overview
- 4.8.3 GlaxoSmithKline Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 GlaxoSmithKline Antiviral Drugs for Influenza Product Portfolio
- 4.8.5 GlaxoSmithKline Recent Developments
- 4.9 Roche
- 4.9.1 Roche Company Information
- 4.9.2 Roche Business Overview
- 4.9.3 Roche Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Roche Antiviral Drugs for Influenza Product Portfolio
- 4.9.5 Roche Recent Developments
- 4.10 Teva Pharmaceuticals
- 4.10.1 Teva Pharmaceuticals Company Information
- 4.10.2 Teva Pharmaceuticals Business Overview
- 4.10.3 Teva Pharmaceuticals Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Teva Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio
- 4.10.5 Teva Pharmaceuticals Recent Developments
5 Global Antiviral Drugs for Influenza Market Scenario by Region
- 5.1 Global Antiviral Drugs for Influenza Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Antiviral Drugs for Influenza Sales by Region: 2021-2032
- 5.2.1 Global Antiviral Drugs for Influenza Sales by Region: 2021-2026
- 5.2.2 Global Antiviral Drugs for Influenza Sales by Region: 2027-2032
- 5.3 Global Antiviral Drugs for Influenza Revenue by Region: 2021-2032
- 5.3.1 Global Antiviral Drugs for Influenza Revenue by Region: 2021-2026
- 5.3.2 Global Antiviral Drugs for Influenza Revenue by Region: 2027-2032
- 5.4 North America Antiviral Drugs for Influenza Market Facts & Figures by Country
- 5.4.1 North America Antiviral Drugs for Influenza Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Antiviral Drugs for Influenza Sales by Country (2021-2032)
- 5.4.3 North America Antiviral Drugs for Influenza Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Antiviral Drugs for Influenza Market Facts & Figures by Country
- 5.5.1 Europe Antiviral Drugs for Influenza Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Antiviral Drugs for Influenza Sales by Country (2021-2032)
- 5.5.3 Europe Antiviral Drugs for Influenza Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Antiviral Drugs for Influenza Market Facts & Figures by Country
- 5.6.1 Asia Pacific Antiviral Drugs for Influenza Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Antiviral Drugs for Influenza Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Antiviral Drugs for Influenza Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Antiviral Drugs for Influenza Market Facts & Figures by Country
- 5.7.1 South America Antiviral Drugs for Influenza Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Antiviral Drugs for Influenza Sales by Country (2021-2032)
- 5.7.3 South America Antiviral Drugs for Influenza Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Antiviral Drugs for Influenza Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Antiviral Drugs for Influenza Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Antiviral Drugs for Influenza Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Antiviral Drugs for Influenza Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Antiviral Drugs for Influenza Sales by Type (2021-2032)
- 6.1.1 Global Antiviral Drugs for Influenza Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Antiviral Drugs for Influenza Sales Market Share by Type (2021-2032)
- 6.2 Global Antiviral Drugs for Influenza Revenue by Type (2021-2032)
- 6.2.1 Global Antiviral Drugs for Influenza Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Antiviral Drugs for Influenza Revenue Market Share by Type (2021-2032)
- 6.3 Global Antiviral Drugs for Influenza Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Antiviral Drugs for Influenza Sales by Application (2021-2032)
- 7.1.1 Global Antiviral Drugs for Influenza Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Antiviral Drugs for Influenza Sales Market Share by Application (2021-2032)
- 7.2 Global Antiviral Drugs for Influenza Revenue by Application (2021-2032)
- 7.2.1 Global Antiviral Drugs for Influenza Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Antiviral Drugs for Influenza Revenue Market Share by Application (2021-2032)
- 7.3 Global Antiviral Drugs for Influenza Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Antiviral Drugs for Influenza Value Chain Analysis
- 8.1.1 Antiviral Drugs for Influenza Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Antiviral Drugs for Influenza Production Mode & Process
- 8.2 Antiviral Drugs for Influenza Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Antiviral Drugs for Influenza Distributors
- 8.2.3 Antiviral Drugs for Influenza Customers
9 Global Antiviral Drugs for Influenza Analyzing Market Dynamics
- 9.1 Antiviral Drugs for Influenza Industry Trends
- 9.2 Antiviral Drugs for Influenza Industry Drivers
- 9.3 Antiviral Drugs for Influenza Industry Opportunities and Challenges
- 9.4 Antiviral Drugs for Influenza Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst